IPHA member company investment in R&D increases significantly
A record level of 98% of Healthcare Professionals have provided named transparency on www.transfersofvalue.ie
IPHA member company investment in R&D increases significantly
Since July 2016, and in line with the IPHA Code of Practice for the Pharmaceutical Industry, companies have disclosed financial transfers of value (ToV)—whether direct or indirect, in cash or in kind—made to Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs). These disclosures are publicly accessible on www.transferofvalue.ie.
At 4pm on June 30th 2025, IPHA published the ToVDisclosure data for 2024. The total ToV amount for 2024 was €32,565,924 which is a 12% increase compared to 2023 data (€29,093,111 for 2023 data).
While IPHA members are required to disclose, currently, of the 51 companies who publish their data through the platform, 11 are non IPHA members, and 40 are IPHA members.
The shared ambition of our member companies is to bring innovative treatments to Irish patients under the guidance of qualified HCPs. We place great value on our longstanding, ethical relationships with doctors, nurses, dentists, and pharmacists, whose experience and insight are essential to advancing the development and appropriate use of new medicines.
To that end IPHA is committed to integrity and transparency in all interactions between our member companies and HCPs and HCOs. Our aim is to reach 100% named disclosure for HCPs, and we will continue to support our member companies in using legitimate interest as a legal basis for making these disclosures under data protection law.
ENDS
For any questions relating to Transfers of Value, please consult the FAQ section on the IPHA website at https://www.ipha.ie/code-of-practice-and-transfers-of-value/transfers-of-value/
